Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: Deferring androgen deprivation therapy

Clinical Genitourinary Cancer

Volumn 11, Issue 1, 2013, Pages 27-32

  Berkovic, Patrick ^a   De Meerleer, Gert ^a   Delrue, Louke ^a   Lambert, Bieke ^a   Fonteyne, Valérie ^a   Lumen, Nicolaas ^a   Decaestecker, Karel ^a   Villeirs, Geert ^a   Vuye, Philippe ^a   Ost, Piet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Low volume metastasis; Oligometastases; SBRT

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BONE METASTASIS; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; SALVAGE STEREOTACTIC BODY RADIOTHERAPY; SCORING SYSTEM; STEREOTACTIC BODY RADIATION THERAPY; UROGENITAL TRACT TOXICITY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS; RADIOSURGERY; RETREATMENT; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84874542651     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.08.003     Document Type: Article

References (24)

1. N. Mottet, J. Bellmunt, M. Bolla EAU guidelines on prostate cancer Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
2. S. Hellman, R.R. Weichselbaum Oligometastases J Clin Oncol 13 1995 8 10
3. D. Singh, W.S. Yi, R.A. Brasacchio Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58 2004 3 10
4. M.T. Milano, A. Philip, P. Okunieff Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses Int J Radiat Oncol Biol Phys 73 2009 832 837
5. P. Rigatti, N. Suardi, A. Briganti Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography Eur Urol 60 2011 935 943
6. J.K. Salama, M.D. Hasselle, S.J. Chmura Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease Cancer 118 2012 2962 2970
7. B.K. Chang, R.D. Timmerman Stereotactic body radiation therapy: a comprehensive review Am J Clin Oncol 30 2007 637 644
8. H. Jadvar Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline J Nucl Med 52 2011 81 89
9. D.T. Schmid, H. John, R. Zweifel Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 2005 623 628
10. P.J. De Visschere, G.O. De Meerleer, J.J. Fütterer Role of MRI in follow-up after focal therapy for prostate carcinoma AJR Am J Roentgenol 194 2010 1427 1433
11. J.O. Barentsz, J. Richenberg, R. Clements ESUR prostate MR guidelines 2012 Eur Radiol 22 2012 746 757
12. A. Dal Pra, F.L. Cury, L. Souhami Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review Curr Oncol 17 2010 28 38
13. U.E. Studer, L. Collette, P. Whelan Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941 949
14. A. Heidenreich, J. Bellmunt, M. Bolla EAU guidelines on prostate cancer Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
15. R.R. Weichselbaum, S. Hellman Oligometastases revisited Nat Rev Clin Oncol 8 2011 378 382
16. Y. Furuya, K. Akakura, S. Akimoto Pattern of progression and survival in hormonally treated metastatic prostate cancer Int J Urol 6 1999 240 244
17. A. Briganti, J.R. Karnes, L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
18. O. Yossepowitch, F.J. Bianco Jr., S.E. Eggener The natural history of noncastrate metastatic prostate cancer after radical prostatectomy Eur Urol 51 2007 940 947 discussion: 947-8
19. M. Picchio, A. Briganti, S. Fanti The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer Eur Urol 59 2011 51 60
20. F. Casamassima, L. Masi, C. Menichelli Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients Tumori 97 2011 49 55
21. B.A. Jereczek-Fossa, L. Fariselli, G. Beltramo Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer Radiother Oncol 93 2009 14 17
22. A. Muacevic, M. Kufeld, C. Rist Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer Urol Oncol 2011 10.1016/j.urolonc.2011.02.023 [Epub ahead of print]
23. M.J. Smith, N.H. Akhtar, S.T. Tagawa The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer Prostate Cancer 2012 2012 280278
24. H.H. Pai, T. Pickles, M. Keyes Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists Can Urol Assoc J 5 2011 173 179